Pfizer Consumer Healthcare announced today that Advil is the official pain reliever of Tough Mudder, a 10 mi to 12 mi obstacle course, as part of the Advil Relief in Action campaign that celebrates volunteers who don’t let pain get in the way of providing relief to others.
The November 2011 expiration of Pfizer's patent on the cholesterol drug Lipitor and Ranbaxy Labs' release of the generic version received significant play in the media, particularly due to the theretofore status of Lipitor (atorvastatin calcium) as the drug with the highest sales in the country, $7.7 billion in the United States, according to healthcare analytics firm IMS Health.
There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.
The Foundation for Health Smart Consumers has announced a major expansion of its smoking cessation initiative through the Inspire Program, which will launch at the annual Retail Clinician Education Congress held in May in Las Vegas.
With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls.
Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.